


PRODUCT INFORMATION



Olmesartan-d₆

Item No. 36324

CAS Registry No.: 1185144-74-4
Formal Name: 4-[1-hydroxy-1-(methyl-d₃)ethyl-2,2,2-d₃]-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
MF: C₂₄H₂₀D₆N₆O₃
FW: 452.5
Chemical Purity: ≥95% (Olmesartan)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Olmesartan-d₆ is intended for use as an internal standard for the quantification of olmesartan (Item No. 23412) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Olmesartan-d₆ is supplied as a solid. A stock solution may be made by dissolving the olmesartan-d₆ in the solvent of choice, which should be purged with an inert gas. Olmesartan-d₆ is soluble in DMSO.

Description

Olmesartan is a non-peptide angiotensin II receptor 1 (AT₁) antagonist (IC₅₀ = 0.0077 μM for the bovine adrenal cortex receptor) and an active metabolite of olmesartan medoxomil (Item No. 11614).¹ It is formed from olmesartan medoxomil by paraoxonase 1 (PON1) in human plasma.² Olmesartan is selective for AT₁ over AT₂ (IC₅₀ = >100 μM for the bovine cerebellar receptor). It reduces contraction of isolated guinea pig aorta induced by angiotensin II (Item No. 17150; pD₂ = 9.9) but not phenylephrine (Item Nos. 17205 | 18619) or potassium chloride. Olmesartan (0.01 and 0.03 mg/kg, i.v.) reduces the angiotensin II-induced pressor response in conscious normotensive rats.

References

1. Mizuno, M., Sada, T., Ikeda, M., *et al.* Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. *Eur. J. Pharmacol.* **285**(2), 181-188 (1995).
2. Ishizuka, T., Fujimori, I., Nishida, A., *et al.* Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: Molecular identification and contribution to plasma metabolism. *Drug Metab. Dispos.* **40**(2), 374-380 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM